New Weight-Loss drug combo tested in early trial

NCT ID NCT07245771

Recruiting now Disease control Sponsor: Ikaria Bioscience Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called RN3161, alone and combined with the weight-loss drug tirzepatide, in 104 adults with overweight or obesity. The main goals are to check safety and how the body handles the drug. Researchers will also measure weight changes. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RN3161 (investigational drug) and tirzepatide
What this could lead to: If successful, this could lead to a new weight-loss treatment option for people with overweight or obesity, possibly more effective when combined with existing drugs.
What could go wrong: This is an early-phase trial with only 104 participants, so results may not apply to everyone. The drug could cause side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY &AMP; OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY &AMP; OVERWEIGHT

Contacts and locations

Locations

Nucleus Network Pty Ltd
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.